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Abstract objective To estimate HIV prevalence in adults who have not tested for HIV using age-specific
mortality rates and to adjust the overall population HIV prevalence to include both tested and
untested adults.
methods An open cohort study was established since 1994 with demographic surveillance system
(DSS) and five serological surveys conducted. Deaths from Kisesa DSS were used to estimate
mortality rates and 95% confidence intervals by HIV status for 3- 5-year periods (1995–1999, 2000–
2004, and 2005–2009). Assuming that mortality rates in individuals who did not test for HIV are
similar to those in tested individuals, and dependent on age, sex and HIV status and HIV, prevalence
was estimated.
results In 1995–1999, mortality rates (per 1000 person years) were 43.7 (95% CI 35.7–53.4) for
HIV positive, 2.6 (95% CI 2.1–3.2) in HIV negative and 16.4 (95% CI 14.4–18.7) in untested. In
2000–2004, mortality rates were 43.3 (95% CI 36.2–51.9) in HIV positive, 3.3 (95% CI 2.8–4.0) in
HIV negative and 11.9 (95% CI 10.5–13.6) in untested. In 2005–2009, mortality rates were 30.7
(95% CI 24.8–38.0) in HIV positive, 4.1 (95% CI 3.5–4.9) in HIV negative and 5.7 (95% CI 5.0–
6.6) in untested residents. In the three survey periods (1995–1999, 2000–2004, 2005–2009), the
adjusted period prevalences of HIV, including the untested, were 13.5%, 11.6% and 7.1%,
compared with the observed prevalence in the tested of 6.0%, 6.8 and 8.0%. The estimated
prevalence in the untested was 33.4%, 21.6% and 6.1% in the three survey periods.
conclusion The simple model was able to estimate HIV prevalence where a DSS provided
mortality data for untested residents.
keywords HIV, prevalence, estimation, model, untested, mortality
Introduction
The number of people living with HIV worldwide in
2007 was estimated at 33.2 million, with subSaharan
Africa (SSA) being the most affected region (WHO
2008). Antenatal clinic (ANC) data obtained from preg-
nant women have been the main source of information
for HIV prevalence trends and estimates of the number
of people living with HIV (Garcıa-Calleja et al. 2006).
The use of ANC data has several constraints such as
under representation of remote rural populations, lack of
data on men and non-pregnant women and limited abil-
ity to assess risk factors of HIV (Mishra et al. 2006).
In recent years, trends and population estimates of HIV
prevalence in SSA are also estimated from household sur-
veys, surveys among high-risk groups (Islam & Conigrave
2008) and population-based surveys such as the demo-
graphic and health surveys (DHS) and AIDS indicator sur-
veys (Mishra et al. 2008). The advantage of using
population-based surveys is that they provide reliable and
nationally representative direct estimates of HIV preva-
lence in countries with generalised epidemics as well as
understanding of the magnitude and spread of epidemics
(Mishra et al. 2008). Another advantage of population-
based surveys is that they can be a source of direct data
on the distribution of HIV infection among different adult
populations, men, women (pregnant & non-pregnant) and
across different geographical regions (Mishra et al. 2006).
The main challenge facing these surveys is a potential
bias caused by non-respondents which raises a major
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concern for analysis and generalisation (Nyirenda et al.
2010). The main reasons for non-response in population-
based surveys are refusal to participate in HIV testing and
absenteeism. Non-response can bias population-based esti-
mates of HIV prevalence if it is systematically associated
with HIV (Marston et al. 2008; Floyd et al. 2013). One
method of overcoming the non-response bias from popula-
tion-based surveys is using mortality rates to estimate HIV
prevalence in non-respondents (Nyirenda et al. 2010) and
adjusting the overall HIV prevalence with a weighted aver-
age of the HIV prevalence in tested and untested residents.
This paper reports sex and age-specific mortality rates
in adults from a population cohort in north-western Tan-
zania. The age-specific mortality rates are used to adjust
the population HIV prevalence for those who did not test
for HIV.
Materials and methods
Data source
This analysis employed data collected since 1994 from a
demographic surveillance study (DSS) in Mwanza Region
in northwest Tanzania, as described by Mwita (Mwita
et al. 2007).
Study design
An open cohort study was established in 1994, and the
population was enumerated every 6 months. Vital registra-
tion data on births and deaths were obtained, and verbal
autopsy interview was used to interpret cause of death.
Five serological surveys have been carried-out in 1994–
1995, 1997–1998, 2000–2001, 2003–2004 and 2006–
2007. During these sero-surveys, adults, aged 15–54 years,
were asked to provide blood samples for anonymous HIV
testing and responded to questionnaires covering sexual
behaviour, use of health services and attitudes towards
HIV (Urassa et al. 2001; Mwita et al. 2007).
Definition of HIV status
HIV status was defined using data from all five HIV sur-
veys between 1994 and 2007. Sero-conversion date was
obtained as the mid-point between the last HIV negative
test result and the first HIV positive test result. Residents
were considered HIV negative from the date of their first
HIV negative test until either the sero-conversion date or
5 years after the last HIV negative test. Residents were
considered HIV positive from the first HIV positive test
or from the sero-conversion date until 20 years after the
last HIV positive test. Residents were considered of
unknown HIV status prior to their first HIV test and for
any period when they could not be defined as HIV posi-
tive or HIV negative according to the above definitions.
Calculation of mortality rates
Total person years of follow up (PYO) was calculated
from 1st January 1995 or the day that the individual
entered the cohort through immigration or on their 15th
birthday. All residents were followed up until the date of
death, out-migration or on their 55th birthday. For resi-
dents who out-migrated and then returned to the DSS, the
time when they were out of the DSS was not included in
the total PYO. Mortality rate was calculated as the quo-
tient of total deaths and PYO. Age-specific mortality rates
were calculated for three 5-year intervals: 1995–1999,
2000–2004 and 2005–2009, these periods corresponding
to a time of increasing HIV prevalence (1995–1999;
Mwaluko et al. 2003), a time when HIV prevalence
reached a plateau (Mwita et al. 2008), and a time of anti-
retroviral therapy (ART) availability (Wringe et al. 2012).
Four age groups were used (15–24 years, 25–34 years,
35–44 years and 45–54 years), and for each period, mor-
tality rates were calculated by age, sex and HIV status.
Principal analytical model
For those with unknown HIV status, the HIV prevalence
was estimated as the weighted average of the mortality
rate of those with known HIV serostatus (Nyirenda et al.
2010). The calculation of the HIV prevalence was
obtained for each group of sex (s), age group (a) and
time period (t), using the formula
Huðs; a; tÞ ¼ Muðs; a; tÞ Mnðs; a; tÞ
Mpðs; a; tÞ Mnðs; a; tÞ ð1Þ
whereby, Mu(s,a,t) = mortality in the unknown HIV,
Mn(s,a,t) = mortality in the known HIV ve, Mp(s,a,
t) = mortality in the known HIV +ve, Hu(s,a,t) = Preva-
lence in the unknown HIV.
For those with known HIV status, the HIV prevalence
in each age, sex and time period Hk(s,a,t) was estimated
as the proportion of the person-years lived by HIV posi-
tive persons, and was calculated as:
Hkðs; a; tÞ ¼
Ypðs; a; tÞ
Ypðs; a; tÞ þ Ynðs; a; tÞ ð2Þ
whereby, Yp(s,a,t) = Total person years lived by those
tested positive, Yn(s,a,t) = Total person years lived by
those tested negative.
© 2014 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 657
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For each age, sex and period, the adjusted HIV preva-
lence (Hw(s,a,t)) was calculated as:
From this, the overall adjusted HIV period prevalence
for each sex aged 15–54 years was obtained by multiply-
ing the adjusted age prevalence of HIV by the proportion
in each age band from a standardised population. To
enable comparison between time periods, the standar-
dised population was taken as the average from the Ki-
sesa cohort across the whole time period 1995–2009.
Ethical clearance
The research received ethical clearance from National
Institute for Medical Research and approved by the Sci-
entific and Ethical Review Committee of the National
AIDS Control Programme of the Ministry of Health and
Social Welfare, Tanzania. This work formed the disserta-
tion project and was approved by the ethics review board
at Kilimanjaro Christian Medical University College.
Results
Participation in HIV testing
Of eligible residents aged 15–54 years, the participation
rate was 72.3% (6566/9078) in 1994/95 and 54.7%
(7171/13 110) in 2006/7. Participation rates were lower
in males (58%) than females (67.5%) for all serological
rounds (Table 1).
Distribution of mortality rates by age, sex and HIV
testing status
Among residents aged 15–44 years of age, in the first
5 years of survey (1995–1999), 320 deaths were
observed in 44 359 PYO, while in 2000–2004, 374
deaths were observed in 53 017 PYO, and in 2005–
2009, 313 deaths in 59 502 PYO (Table 2). In HIV neg-
ative females, mortality rates across the three periods
remained similar, while in HIV negative males, an
increased mortality rate (4.6 deaths per 1000 PYO) was
observed in the final period (2005–2009). HIV positive
males and females had significantly higher mortality than
HIV negatives, in all survey rounds (Figure 1). The over-
all mortality rate ratios (MRR) in females and males
were between 13.6 and 19.4 for the first two periods
(1995–1999 and 2000–2004). In the third period (2005–
2009), the MRR had dropped to 6.6 in males and 9.3 in
females (Table 2).
In the first two periods (1995–1999 and 2000–2004)
for both males and females, the overall mortality for
untested residents was 2–2.5 times as high as those who
had tested for HIV (Table 3). In the last 5 years of survey
2005–2009, the mortality rates for tested and untested
individuals were lower than previous years of survey. In
the final period (2005–2009), the mortality rates in
untested residents were similar to those in residents who
had tested for HIV (Table 3).
Adjusted HIV prevalence
Estimating the period prevalence of HIV from the mortal-
ity rates showed that HIV prevalence for adults who did
not test for HIV in 1995–1999 was significantly higher
across all age groups and sex. A total of 30 527 person-
years were contributed by adults who tested negative;
and 2004 person years were contributed by HIV positive
individuals, giving an observed period prevalence of
6.2% for tested residents in 1995–1999. The mortality
for HIV negative individuals was 2.6 deaths per 1000
Table 1 Participation rate in HIV testing among adults aged 15–44 years of age
Serology round
Males Females Both sexes
Tested Percent Tested Percent Tested Percent
1994/1995 3092 70.2 3474 74.3 6566 72.3
1996/1997 3337 66.1 4011 74.0 7348 70.2
1999/2000 2991 55.4 3992 67.3 6983 61.6
2003/2004 3585 55.5 4536 64.2 8121 60.1
2006/2007 2992 47.7 4179 61.1 7171 54.7
Total 15 997 58.0 20 192 67.5 36 189 62.9
Hwðs; a; tÞ ¼ Huðs; a; tÞ  Yuðs; a; tÞ þHkðs; a; tÞ  ½Ypðs; a; tÞ þ Ynðs; a; tÞ
Ypðs; a; tÞ þ Ynðs; a; tÞ þ Yuðs; a; tÞ ð3Þ
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PYO, 44.4 deaths per 1000 PYO for HIV positive
individuals and 12.8 deaths per 1000 PYO for individuals
who did not test for HIV, giving a period prevalence of
24.5% for residents who did not test in 1995–1999. Tak-
ing into account the period prevalence of HIV and person
years for HIV negative, HIV positive and untested indi-
viduals (11 829 PYO), the overall period prevalence of
HIV adjusted for the whole population was 11.1% in the
period of 1995–1999.
In the period of 2000–2004, a total of 32 761 person
years of follow up were recorded among HIV negatives,
2399 person years for HIV positives and 17 856 PYO
for the untested, making an overall period prevalence
of 6.8% for those who tested for HIV. The mortality
rates (death per 1000 PYO) for HIV negatives, HIV
positives and untested were 2.5, 39.2 and 11.1,
Table 2 Mortality rates and person years of follow up in HIV negative and HIV positive adults aged 15–44 years from 1995 through
2009
HIV negative HIV positive
MR ratioDeaths PY MR/1000
95% CI
Deaths PY MR/1000
95% CI
Lower Upper Lower Upper
1995–1999 – Males
15–24 16 7681.8 2.1 1.3 3.4 1 143.3 7.0 1.0 49.5 3.3
25–34 14 4336.3 3.2 1.9 5.5 20 369.6 54.1 34.9 83.9 16.9
35–44 12 2850.5 4.2 2.4 7.4 20 269.6 74.2 47.9 110.0 17.7
Total 42 14 868.7 2.8 2.1 3.8 41 782.5 52.4 38.6 71.2 18.7
1995–1999 – Females
15–24 13 6649.7 2.0 1.1 3.4 6 394.8 15.2 6.8 33.8 7.6
25–34 11 5445.1 2.0 1.1 3.6 31 596.6 52.0 36.5 73.9 26.0
35–44 13 3563.0 3.6 2.1 6.3 11 229.8 47.9 26.5 86.4 13.3
Total 37 15 657.7 2.4 1.7 3.3 48 1221.2 39.3 29.6 52.2 16.4
2000–2004 – Males
15–24 8 7983.1 1.0 0.5 2.0 3 236.3 12.7 4.1 39.4 12.7
25–34 9 4442.9 2.0 1.1 3.9 16 365.9 43.7 26.8 71.4 21.9
35–44 16 3128.1 5.1 3.1 8.3 19 328.4 57.9 36.9 90.7 11.4
Total 33 15 554.1 2.1 1.5 3.0 38 930.6 40.8 29.7 56.1 19.4
2000–2004 – Females
15–24 12 6965.3 1.7 1.0 3.0 8 409.7 19.5 9.8 39.0 11.5
25–34 14 5813.8 2.4 1.4 4.1 28 691.3 40.5 28.0 58.7 16.9
35–44 23 4427.6 5.2 3.5 7.8 20 367.8 54.4 35.1 84.3 10.5
Total 49 17 206.8 2.8 2.2 3.8 56 1468.8 38.1 29.3 49.5 13.6
2005–2009 – Males
15–24 19 7119.7 2.7 1.7 4.2 1 212.0 4.7 0.7 33.5 1.7
25–34 14 3289.6 4.3 2.5 7.2 14 288.5 48.5 28.7 81.9 11.3
35–44 26 2461.1 10.6 7.2 15.5 10 325.2 30.7 16.5 57.1 2.9
Total 59 12 870.4 4.6 3.6 5.9 25 825.7 30.3 20.5 44.8 6.6
2005–2009 – Females
15–24 6 5777.4 1.0 0.5 2.3 4 314.0 12.7 4.8 33.9 12.7
25–34 15 4806.4 3.1 1.9 5.2 14 636.7 22.0 13.0 37.1 7.1
35–44 19 3903.3 4.9 3.1 7.6 20 509.0 39.3 25.4 60.9 8.0
Total 40 14 487.1 2.8 2.0 3.8 38 1459.6 26.0 18.9 35.8 9.3
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Figure 1 Trends of mortality rates in three survey periods.
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respectively, giving a period prevalence of 23.4% for
the untested. The adjusted period prevalence of HIV for
the whole population was 12.4% in this survey period
(Figure 2).
Individuals who tested negative for HIV in the time
period of 2005–2009 were followed up for 27 357 PYO;
HIV positives were followed up for 2285 PYO and
untested for 29 859 PYO, making a period prevalence of
7.7% for the tested individuals. Using the overall mortal-
ity rates of 3.6 deaths per 1000 PYO for the HIV nega-
tive individuals, 27.6 deaths per 1000 PYO for HIV
positive and 5.1 deaths per 1000 PYO for untested indi-
viduals, the estimated period prevalence of HIV for the
untested residents was 6.0%. The weighted period preva-
lence of HIV for the tested and untested individuals was
6.9% in this time interval for adults aged 15–44 years
(Figure 2).
Table 3 Mortality rates and person years of follow up in adults aged 15–44 years, who tested for HIV, and who did not test for HIV,
from 1995 through 2009
Did not test Tested
MR ratioDeaths PY MR/1000
95% CI
Deaths PY MR/1000
95% CI
Lower Upper Lower Upper
1995–1999 – Males
15–24 17 2650.0 6.4 4.0 10.3 17 7825.1 2.2 1.4 3.5 3.0
25–34 32 2117.2 15.1 10.7 21.4 34 4705.9 7.2 5.2 10.1 2.1
35–44 30 1287.6 23.3 16.3 33.3 32 3120.1 10.3 7.3 14.5 2.3
Total 79 6054.8 13.0 10.5 16.3 83 15 651.2 5.3 4.3 6.6 2.5
1995–1999 – Females
15–24 24 3434.6 7.0 4.7 10.4 19 7044.5 2.7 1.7 4.2 2.6
25–34 31 1655.9 18.7 13.2 26.6 42 6041.7 7.0 5.1 9.4 2.7
35–44 18 683.9 26.3 16.6 41.8 24 3792.8 6.3 4.2 9.4 4.2
Total 73 5774.4 12.6 10.1 15.9 85 16 878.9 5.0 4.1 6.2 2.5
2000–2004 – Males
15–24 24 3931.7 6.1 4.1 9.1 11 8219.3 1.3 0.7 2.4 4.6
25–34 35 3364.9 10.4 7.5 14.5 25 4808.8 5.2 3.5 7.7 2.0
35–44 46 2123.6 21.7 16.2 28.9 35 3456.5 10.1 7.3 14.1 2.1
Total 105 9420.2 11.1 9.2 13.5 71 16 484.7 4.3 3.4 5.4 2.6
2000–2004 – Females
15–24 24 4883.2 4.9 3.3 7.3 20 7375.0 2.7 1.7 4.2 1.8
25–34 43 2557.0 16.8 12.5 22.7 42 6505.1 6.5 4.8 8.7 2.6
35–44 26 995.8 26.1 17.8 38.3 43 4795.4 9.0 6.7 12.1 2.9
Total 93 8436.0 11.0 9.0 13.5 105 18 675.6 5.6 4.6 6.8 2.0
2005–2009 – Males
15–24 16 6244.6 2.6 1.6 4.2 20 7331.7 2.7 1.8 4.2 0.9
25–34 33 5594.8 5.9 4.2 8.3 28 3578.1 7.8 5.4 11.3 0.8
35–44 32 3489.0 9.2 6.5 13.0 36 2786.3 12.9 9.3 17.9 0.7
Total 81 15 328.5 5.3 4.3 6.6 84 13 696.2 6.1 5.0 7.6 0.9
2005–2009 – Females
15–24 19 7687.7 2.5 1.6 3.9 10 6091.4 1.6 0.9 3.1 1.5
25–34 29 4666.3 6.2 4.3 8.9 29 5443.1 5.3 3.7 7.7 1.2
35–44 22 2176.6 10.1 6.7 15.4 39 4412.2 8.8 6.5 12.1 1.1
Total 70 14 530.5 4.8 3.8 6.1 78 15 946.7 4.9 3.9 6.1 1.0
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Discussion
Many studies conducted in subSaharan Africa (Garcıa-
Calleja et al. 2006; Marston et al. 2008; Nyirenda et al.
2010) have found poor participation in HIV testing par-
ticularly among males, giving rise to potential bias in the
estimated HIV prevalence. We used the observed deaths
and person years contributed by the residents in Kisesa
DSS to adjust the HIV prevalence for the whole popula-
tion in Kisesa. Based on the observed mortality, our
analysis showed, in the period from 1995 to 2004, resi-
dents who did not test for HIV had significantly higher
period prevalence of HIV than residents who tested for
HIV across both sexes and all age groups. We calculated
weighted period prevalence of HIV for the whole popula-
tion and found that the weighted HIV prevalence was
80% higher than the observed HIV prevalence in both
1995–1999 and 2000–2005. However, for the period
2005–2009, we did not find increased mortality among
those who had not tested for HIV, and the weighted HIV
prevalence was 10% lower than that observed in those
that tested for HIV in the surveys.
In this analysis, the proportion of non-respondents
increased in each subsequent serological survey, with a
non-participation rate of 28% in the first sero–survey
and increased to 45% in the last sero-survey. These find-
ings are similar to rural South Africa (Nyirenda et al.
2010) and Malawi (Mishra et al. 2008). Several surveys
mentioned reasons for not consenting for HIV testing as
absenteeism (Marston et al. 2008; Reniers & Eaton
2009) and knowing that one is HIV positive already is
less likely to participate, which may lead to underestima-
tion of HIV prevalence (Floyd et al. 2013).
We investigated the pattern of mortality from 1995 to
2009 and found that mortality rates among HIV negative
residents did not change much over the 15 years period.
However, the mortality for HIV-positive and untested
decreased in each subsequent survey round. Although the
mortality rate for HIV-negative residents did not change
significantly with time, mortality rates for HIV-positive
residents were 17 times higher than that of HIV-negative
residents in 1995–1999, 13 times higher than HIV nega-
tives in 2000–2005 and eight times higher in 2005–2009
survey rounds. This was similar to the findings from
South Africa, where the mortality rate for those who
tested positive was 11–19 times higher than mortality in
HIV-negative individuals (Nyirenda et al. 2007). HIV-
positive males had slightly higher mortality rates than
females in all survey years and mortality increased with
age for both males and females. The proportion of Kisesa
residents who die between the age of 15 years and
60 years was 49% and 46% for men and women,
respectively, and attributed this increase of mortality to
AIDS epidemic (Urassa et al. 2001). There has been a
significant decrease of mortality for all residents in Kisesa
cohort Michael et al. 2014). The decrease of mortality
among HIV-positive residents may be explained by the
introduction of ART and better control and treatment of
opportunistic infections.
Using DHS data from prior to the advent of ART in
14 African countries, including Tanzania, Mishra showed
that untested males and females had significantly higher
predicted prevalence of HIV than tested individuals
(Mishra et al. 2008). Mishra did not use our model;
instead, they used regression model to predict HIV preva-
lence among non-testers using several indicators includ-
ing, age, education, wealth index, residence, marital
status, religion and geographic region. This study adapted
the model that was previously applied to longitudinal
data in KwaZulu-Natal in South Africa by Nyirenda
et al. (2010). We had similar findings to Nyirenda in the
periods up to 2005, with HIV prevalence in all age
groups higher in those who had not tested for HIV com-
pared with those who had tested. However, in the period
between 2005 and 2009, when ART became available to
the population, there was little difference in the mortality
rates and the estimated HIV prevalence between those
who had tested for HIV and those who had not tested
for HIV.
This analysis makes the assumption that among those
who test and those who do not test, the mortality rates
for HIV positive subjects are the same, and the mortality
rates for HIV negative subjects are the same. In the final
period of analysis (2005–2009), when ART became avail-
able in Tanzania, as expected, the mortality rates in those
who did not test was higher than the mortality rates in
the HIV negatives and lower than the mortality rates in
the HIV positives. However, unlike in the previous peri-
ods, the estimated period prevalence of HIV in the
untested was lower than the HIV prevalence in the tested.
This could have been because some of those who did not
take the anonymous test for HIV in our survey had previ-
ously tested HIV positive and because they knew their
HIV status had been able to access ART, and thereby
had improved survival over those who did test for HIV
in our surveys. With the advent of ART, the mortality
rates of HIV positive people who test and the mortality
rates of HIV positive people who do not test differ, and
the assumption behind this adjustment to the observed
HIV prevalence does not hold.
In the first two periods, this model showed that if we
do not take into account HIV prevalence in the un-tested
individuals, HIV prevalence estimated from individuals
who consented to HIV testing can be underestimated.
© 2014 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 661
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Similar findings have been documented from the analysis
of eight DHS and one AIDS Indicator Survey in African
countries (Marston et al. 2008). However, with the
advent of ART, the relationship between HIV testing and
mortality has changed, and the methods used in the
analysis may not be useful to obtain an adjusted HIV
prevalence in the population.
This model did not use detailed demographic data such
as mobility, occupation, alcohol use, number of sexual
partners, marital status, age at first sex, religion or any
complex mathematical computations. It only used mortal-
ity and HIV testing status to estimate HIV prevalence for
non-respondents. The model has been commended by
Nyirenda et al. in South Africa (Nyirenda et al. 2010) to
be used in DSS settings across Africa, but this may not be
suitable with the advent of ART. Other models used to
estimate HIV prevalence for non-testers such as multiple
imputations (Barnighausen et al. 2008) and regression
equations (Mishra et al. 2008) use detailed demographic
characteristics which may suffer from reporting bias. In
addition to that, detailed demographic characteristics are
not uniformly collected in many DSS as compared to
mortality data so relying on demographic data can lead
to biased estimates (Nyirenda et al. 2010). One advan-
tage of the mortality model is that it can be used when-
ever there is prospective mortality follow-up data for
individuals who participated in sero-survey and those
who did not participate even if there was only one sero-
survey conducted (Nyirenda et al. 2010). Moreover,
researchers who opt to use this model do not need
advanced mathematical expertise instead they just need
to know simple arithmetic calculations to apply the
model.
This model cannot be applied to the data from cross-
sectional studies where point prevalence is used as a mea-
sure of disease frequency. The model needs prospective
adult mortality data for the calculation of the period
prevalence of HIV in a specified population at risk that
have the disease of interest over a specified period of
time. Many national estimates of HIV prevalence uses
data from cross-sectional surveys which cannot be
accommodated by this model (Islam & Conigrave 2008).
Conclusion
This study has found poor participation in HIV testing
among residents in Kisesa ward particularly among
males, and the proportion of residents testing maintained
gradual decrease for each subsequent year of sero-survey.
Mortality for non-respondents was significantly higher
than HIV-negative residents. Moreover, mortality
increased with age of residents and was slightly higher
among untested males than untested females. HIV preva-
lence for non-respondents was significantly higher in
1994–2004 survey years than prevalence of tested resi-
dents, and may provide an accurate adjustment for the
calculation of the population HIV prevalence. However,
with the advent of ART, this model may not allow an
accurate adjustment for the population HIV prevalence.
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